Accepted Manuscript

Title: Evaluation of the safety of a protocol for switching venom immunotherapy products

Author: Erminia Ridolo, Irene Martignago, Giovanni Passalacqua, Marina


Mauro, Cristoforo Incorvaia

PII: S1081-1206(18)30033-4

DOI: https://doi.org/10.1016/j.anai.2018.01.026

Reference: ANAI 2447

To appear in: Annals of Allergy, Asthma & Immunology



Please cite this article as: Erminia Ridolo, Irene Martignago, Giovanni Passalacqua, Marina Mauro, Cristoforo Incorvaia, Evaluation of the safety of a protocol for switching venom immunotherapy products, *Annals of Allergy, Asthma & Immunology* (2018), https://doi.org/10.1016/j.anai.2018.01.026.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

1	
2	
3	Evaluation of the safety of a protocol for switching venom immunotherapy products
4	Erminia Ridolo¹, PhD, Irene Martignago, MD, Giovanni Passalacqua², PhD, Marina Mauro³,MD, Cristoforo
5 6	Incorvaia ⁴ ,MD.
7	1Department of Clinical & Experimental Medicine, University of Parma, Parma, Italy.
8	² Allergy & Respiratory Diseases, Ospedale Policlinico San Martino, Genoa .
9	³ Allergy Unit, Sant'Anna Hospitalm ASST Lariana, Como, Italy.
10	⁴ Cardiac/Pulmonary Rehabilitation, ASST Pini/CTO, Milan, Italy.
11	caralacy rannonary remainitation, 7,551 rany cro, which, reary.
12	Acknowledgments
13	C Incorvaia has been a scientific consultant for Bayer S.p.A. and Stallergenes S.r.l. The authors have no
14	other relevant affiliations or financial involvement with any organization or entity with a financial interest
15	in or financial conflict with the subject matter or materials discussed in the manuscript apart from those
16	disclosed.
17	
18	Corresponding Author: Erminia Ridolo, Department of Medicine and Surgery, University of Parma, via
19	Gramsci 14, 43126, Parma, Italy. Phone: +390521702028; Fax: +390521703920, e-mail:
20	erminia.ridolo@unipr.it .
21	Crimina.naoio@ampr.ic.
22	Keywords : Hymenoptera venom allergy, Immunotherapy, Venom shortage, Safety, Mastocytosis.
23	
24	Abbreviations/Acronyms:
25	IV: Intravenous
26	VIT: Venom immunotherapy
27	
28	Funding Source: None.
29	
30	Trial registration: Not applicable
31	
32	Conflict of Interest: C Incorvaia has been a scientific consultant for Bayer S.p.A. and Stallergenes S.r.l. The
33	authors have no other relevant affiliations or financial involvement with any organization or entity with a
34	financial interest in or financial conflict with the subject matter or materials discussed in the manuscript
35	apart from those disclosed.
36	
37	Word Count: 993
38	Figures: None
39	Tables: 1.
40	
41	

Download English Version:

https://daneshyari.com/en/article/8711781

Download Persian Version:

https://daneshyari.com/article/8711781

<u>Daneshyari.com</u>